We detected Axl expression on CLL B-cells from all CLL patients tested, albeit at variable levels, with a median level of 58.9% (range 2.7-91.3%) (Figure 2A) and expression remained mostly unaltered over time during ibrutinib treatment (Figure 2A). This evidence concerns the gene AXL and B-cell chronic lymphocytic leukemia.